Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant.

Flavio G Vincenti Oriol BestardAmarpali BrarJosep M Cruzado Daniel Seron Ahmed Osama Gaber Nicole M Ali Anat Roitberg TamburHelen LeeGiovanni AbbadessaJo-Anne PaulMarkus Dudek Ruby J Siegel Alba TorijaDorothee SemiondLucie LépineNils TernesRobert A MontgomeryMark Stegall

Published in: Journal of the American Society of Nephrology : JASN (2023)

In this open-label trial, isatuximab was well tolerated and resulted in a durable decrease in anti-HLA antibodies with partial desensitization activity.

Keyphrases

open label
end stage renal disease
clinical trial
phase iii
phase ii
study protocol
chronic kidney disease
ejection fraction
newly diagnosed
prognostic factors
peritoneal dialysis
randomized controlled trial
radiation therapy
phase ii study
patient reported
locally advanced